TSHA - NASDAQ

Taysha Gene Therapies, Inc.

TSHA·NASDAQ

$5.79

+1.7%

HealthcareBiotechnology

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.45B

EPS-0.3400

P/E Ratio-17.01

Earnings Date08/11/2026

tsha

Additional Paid-In Capital

Last Annual Value

958.43M

3-Year CAGR

34%

5-Year CAGR

25%

10-Year CAGR

99%

Adjust for Inflation

Taysha Gene Therapies, Inc. Competitors Analysis of Additional Paid-In Capital

TSHA · NASDAQ

Company	Additional Paid-In Capital	CAGR 3Y	CAGR 5Y	CAGR 10Y
Taysha Gene Therapies, Inc. NASDAQ:TSHA	958.43M	17.7%	23.7%	N/A
Atai Beckley Inc. NASDAQ:ATAI	1.60B	26.3%	17.1%	N/A
Nektar Therapeutics NASDAQ:NKTR	3.85B	2.2%	1.8%	6.2%
Dianthus Therapeutics, Inc. NASDAQ:DNTH	829.60M	47.6%	10.7%	N/A
Xencor, Inc. NASDAQ:XNCR	1.43B	8.1%	7.0%	10.0%
Enliven Therapeutics, Inc. NASDAQ:ELVN	806.37M	26.3%	222.4%	N/A
AnaptysBio, Inc. NASDAQ:ANAB	809.76M	4.8%	3.6%	47.4%
Sana Biotechnology, Inc. NASDAQ:SANA	2.01B	7.3%	5.8%	N/A
BridgeBio Oncology Therapeutics Inc. NASDAQ:BBOT	767.64M	3050.8%	691.5%	N/A

Taysha Gene Therapies, Inc. Fair Value Envelope

TSHA · NASDAQ

Our analysis suggests that TSHA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.785, this represents a potential HIDDEN relative to our calculated worth for Taysha Gene Therapies, Inc..

HIDDEN

Intrinsic Value

Current Price: $5.785

Related Guides

Blog Categories

Continue your TSHA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.